Literature DB >> 8880085

Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis.

G Emilien1, J M Maloteaux, A Seghers, G Charles.   

Abstract

The hypothesis that lithium is the most appropriate and efficacious pharmacological treatment in the therapy of manic-depressive illness was examined in a meta-analysis. The efficacy of lithium was compared with that of the antiepileptics, carbamazepine and valproic acid. Data sources include the Medline database and relevant references from articles. Only randomised controlled clinical trials with a double-blind assessment of outcomes were included. Lithium levels were required to be within the therapeutic range of 0.4-1.5 mmol/l. The effect sizes were measured by the odds ratio using the Mantel-Haenszel method. No significant difference was observed between the treatment effect of the 3 drugs compared. While the efficacy of the 3 treatments was identical, there is a general tendency in favour of the antiepileptics in the treatment of manic depression with regard to adverse events and treatment tolerance. The impact and importance of this study seriously question the relevance of today's practice of prescribing lithium in the acute management of manic-depressive illness.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880085     DOI: 10.1016/0924-977x(96)00029-6

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  12 in total

1.  Efficacy and Safety of Once- versus Twice-Daily Carbamazepine Extended-Release Capsules for the Treatment of Manic Symptoms in Patients with Bipolar I Disorder.

Authors:  Richard H Weisler; Amir H Kalali; Andrew J Cutler; Thomas D Gazda; Lawrence Ginsberg
Journal:  Psychiatry (Edgmont)       Date:  2008-03

2.  Time to rehospitalization in patients with bipolar I disorder on lithium or valproate with adjunctive antipsychotics.

Authors:  Ching-Hua Lin; Ching-Wen Huang; Cheng-Chung Chen; Yu-Fen Hsu; Wen-Ho Chang; Hsien-Yuan Lane
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 4.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 5.  Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.

Authors:  Ayşegül Yildiz; Eduard Vieta; Stefan Leucht; Ross J Baldessarini
Journal:  Neuropsychopharmacology       Date:  2010-10-27       Impact factor: 7.853

6.  Reversible lithium neurotoxicity: review of the literatur.

Authors:  Ivan Netto; Vivek H Phutane
Journal:  Prim Care Companion CNS Disord       Date:  2012

Review 7.  The effects of lithium on cognition: an updated review.

Authors:  Arlin K Pachet; Amy M Wisniewski
Journal:  Psychopharmacology (Berl)       Date:  2003-09-19       Impact factor: 4.530

Review 8.  Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Mixed versus manic bipolar disorder: a comparison of demographic, symptomatic, and treatment differences.

Authors:  Nurun N Shah; Patricia M Averill; Andrew Shack
Journal:  Psychiatr Q       Date:  2004

10.  Carbamazepine extended-release capsules in bipolar disorder.

Authors:  Richard H Weisler
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.